Novartis’s Capmatinib Shows High Response Rates In NSCLC

AACR Lung Cancer Plenary Also Included Spectrum’s Poziotinib

 
• By Mandy Jackson
  
lung illustration
Phase II capmatinib and poziotinib data were presented at AACR
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D